

**Cyient Israel India Limited**  
**Balance Sheet as at March 31, 2025**

All amounts in ILS, unless otherwise stated)

Particulars	Notes	As at March 31, 2025	As at March 31, 2024
<b>ASSETS</b>			
<b>Current assets</b>			
Financial assets			
(a) Trade receivables	3	2,136,606	2,136,606
(b) Cash and cash equivalents	4	37,947	37,947
(c) Other financial assets	5	15,000	15,000
Income tax assets	11	183,554	183,554
Other current assets	6	290,266	290,266
<b>Total current assets</b>		<b>2,663,373</b>	<b>2,663,373</b>
<b>Total assets</b>		<b>2,663,373</b>	<b>2,663,373</b>
<b>EQUITY AND LIABILITIES</b>			
<b>EQUITY</b>			
Equity share capital	7	1,817,100	1,817,100
Other equity	8	297,049	307,049
<b>Total equity</b>		<b>2,114,149</b>	<b>2,124,149</b>
<b>LIABILITIES</b>			
<b>Current liabilities</b>			
Financial liabilities			
Trade payables	9	505,651	495,651
Other current liabilities	10	43,573	43,573
<b>Total current liabilities</b>		<b>549,224</b>	<b>539,224</b>
<b>Total liabilities</b>		<b>549,224</b>	<b>539,224</b>
<b>Total equity and liabilities</b>		<b>2,663,373</b>	<b>2,663,373</b>
Corporate information and significant accounting policies	1 & 2		
Accompanying notes form an integral part of the financial statements			

As per our report of even date

For **G. P. Associates**

Chartered Accountants

Registration number: 0067345

For **Cyient Limited**

**CA. K. Abhiram**

Partner

Membership No.: 239219

**Prabhakar Atla**

President and Chief Financial Officer

Place: Hyderabad

Date: April 23, 2025

Place: Hyderabad

Date: April 23, 2025

<b>Cyient Israel India Limited</b> <b>Statement of Profit and Loss for the year ended March 31, 2025</b> (All amounts in ILS, unless otherwise stated)			
Particulars	Note	For the year ended March 31, 2025	For the year ended March 31, 2024
<b>INCOME</b>			
Revenue from operations	12	-	-
Other income	13	-	-
<b>Total income</b>		-	-
<b>EXPENSES</b>			
Employee benefits expense	14	-	-
Other expenses	15	10,000	10,000
<b>Total expenses</b>		<b>10,000</b>	<b>10,000</b>
<b>Profit before tax</b>		<b>(10,000)</b>	<b>(10,000)</b>
<b>Tax expense</b>			
Current tax	11	-	-
<b>Total tax expense</b>		-	-
<b>Profit for the year</b>		<b>(10,000)</b>	<b>(10,000)</b>
<b>Other comprehensive income (OCI)</b>		-	-
<b>Total other comprehensive income for the year</b>		-	-
<b>Total comprehensive income for the year</b>		<b>(10,000)</b>	<b>(10,000)</b>
<b>Earnings per equity share</b> (par value of ILS 1 each)			
Basic and diluted		(0.01)	(0.01)
Corporate information and significant accounting policies	1 & 2		
Accompanying notes form an integral part of the financial statements			
As per our report of even date			
<b>For G. P. Associates</b> Chartered Accountants Registration number: 006734S  <b>CA. K. Abhiram</b> Partner Membership No.: 239219  Place: Hyderabad Date: April 23, 2025		<b>For Cyient Limited</b>  <b>Prabhakar Atla</b> President and Chief Financial Officer  Place: Hyderabad Date: April 23, 2025	

<b>Cyient Israel India Limited</b> <b>Cash flow statement for the year ended March 31, 2025</b> (All amounts in ILS, unless otherwise stated)		
Particulars	Year ended	
	March 31, 2025	March 31, 2024
<b>A. CASH FLOW FROM OPERATING ACTIVITIES</b>		
Profit for the year	(10,000)	(10,000)
Adjustments for:		
Net unrealised exchange (gain)/loss	-	-
Operating profit before working capital changes	(10,000)	(10,000)
Changes in working capital		
Adjustments for (increase) / decrease in operating assets:		
Trade receivables	-	-
Other assets	-	-
Adjustments for increase / (decrease) in operating liabilities:		
Trade payables	10,000	-
Other current liabilities	-	-
Cash generated from operations	-	(10,000)
Net income taxes paid (net)	-	-
Net cash flow used in operating activities	-	(10,000)
Net increase in cash and cash equivalents	-	(10,000)
Cash and cash equivalents at the beginning of the year	37,947	47,947
Cash and cash equivalents at the end of the year (refer note (i) below)	37,947	37,947
Notes :		
(i) Cash and cash equivalents comprises of:		
in current accounts (refer note 4)	37,947	37,947
	37,947	37,947
Accompanying notes form an integral part of the financial statements As per our report of even date		
<div> <div> <b>For G. P. Associates</b>  Chartered Accountants  Registration number: 006734S </div> <div> <b>For Cyient Limited</b>           <b>Prabhakar Atla</b>  President and Chief Financial Officer </div> </div>		
<div> <div> <b>CA. K. Abhiram</b>  Partner  Membership No.: 239219 </div> <div> Place: Hyderabad  Date: April 23, 2025 </div> </div>		
<div> <div> <b>CA. K. Abhiram</b>  Partner  Membership No.: 239219 </div> <div> Place: Hyderabad  Date: April 23, 2025 </div> </div>		

**Cyient Israel India Limited****Statement of changes in equity for the year ended March 31, 2024**

(All amounts in ILS, unless otherwise stated)

**A. Equity share capital**

Particulars	Note	Amount
Balance as at April 01, 2023	7	1,817,100
Balance as at March 31, 2024	7	1,817,100
Balance as at March 31, 2025	7	1,817,100

**B. Other Equity**

Particulars	Note	Retained earnings	Total
Balance as at April 1, 2023		317,049	317,049
Profit for the year	8	(10,000)	(10,000)
Balance as at March 31, 2024		307,049	307,049
Profit for the year	8	(10,000)	(10,000)
Balance as at March 31, 2025		297,049	297,049

Accompanying notes form an integral part of the financial statements

As per our report of even date

**For G. P. Associates**

Chartered Accountants

Registration number: 006734S

**For Cyient Limited****CA. K. Abhiram**

Partner

Membership No.: 239219

**Prabhakar Atla**

President and Chief Financial Officer

Place: Hyderabad

Date: April 23, 2025

Place: Hyderabad

Date: April 23, 2025

### 3. Trade receivables

Particulars	As at	
	March 31, 2025	March 31, 2024
<b>Trade receivables</b>		
Unsecured, considered good *	2,136,606	2,136,606
Trade receivables - significant increase in credit risk	-	-
Less: Expected credit loss allowance	-	-
<b>Total</b>	<b>2,136,606</b>	<b>2,136,606</b>

\* Includes amount receivable from related parties.

#### Note:

##### Expected Credit Loss(ECL):

The company's exposure to credit risk is influenced mainly by the individual characteristics of each customer. Credit risk is managed through credit approvals, establishing credit limits and continuously monitoring the creditworthiness of customers to which the company grants credit terms in the normal course of business. The average credit period is between 60-90 days. Before accepting any new customer, the Company uses an internal credit scoring system to assess the potential customer's credit quality and defines credit limits for each customer. Limits and scoring attributed to customers are reviewed once a year.

Ageing for trade receivables	As at March 31, 2025						Total
	Not Due	Less than 6 months	6 months to 1 year	1 - 2 years	2 - 3 years	More than 3 years	
<b>Undisputed trade receivables</b>							
Considered good	-	-	23,359	1,412,117	269,030	431,699	2,136,206
Credit impaired	-	-	-	-	-	-	-
<b>Disputed trade receivables</b>							
Considered good	-	-	-	-	-	-	-
Credit impaired	-	-	-	-	-	-	-
<b>Total</b>	-	-	23,359	1,412,117	269,030	431,699	2,136,206
Less : Allowance for expected credit loss	-	-	-	-	-	-	-
<b>Balance at the end of the year</b>	-	-	23,359	1,412,117	269,030	431,699	<b>2,136,206</b>

Ageing for trade receivables	As at March 31, 2024						Total
	Not Due	Less than 6 months	6 months to 1 year	1 - 2 years	2 - 3 years	More than 3 years	
<b>Undisputed trade receivables</b>							
Considered good	-	23,359	1,412,117	269,030	431,699	-	2,136,206
Credit impaired	-	-	-	-	-	-	-
<b>Disputed trade receivables</b>							
Considered good	-	-	-	-	-	-	-
Credit impaired	-	-	-	-	-	-	-
<b>Total</b>	-	23,359	1,412,117	269,030	431,699	-	2,136,206
Less : Allowance for expected credit loss	-	-	-	-	-	-	-
<b>Balance at the end of the year</b>	-	23,359	1,412,117	269,030	431,699	-	<b>2,136,206</b>

### 4. Cash and cash equivalents

Particulars	As at	
	31-Mar-25	31-Mar-24
Balances with banks in current accounts	37,947	37,947
<b>Total</b>	<b>37,947</b>	<b>37,947</b>

### 5. Other financial assets

Particulars	As at	
	31-Mar-25	31-Mar-24
<b>Current (at amortised cost)</b>		
Security Deposits - Unsecured, considered good	15,000	15,000
<b>Total</b>	<b>15,000</b>	<b>15,000</b>

### 6. Other assets

Particulars	As at	
	31-Mar-25	31-Mar-24
<b>Current :</b> <b>(at amortised cost)</b>		
Advance To Suppliers	290,266	290,266
<b>Total other current assets</b>	<b>290,266</b>	<b>290,266</b>

7. Equity share capital

Particulars	As at	
	March 31, 2025	March 31, 2024
Issued and subscribed capital:		
1,817,100 (March 31, 2022 : 1,817,000) fully paid up equity shares of ILS 1/- each	1,817,100	1,817,100
Total	1,817,100	1,817,100

(A) Reconciliation of the number of shares outstanding:

Particulars	As at March 31, 2025		As at March 31, 2024	
	Number of shares held	Amount	Number of shares held	Amount
Opening Balance	1,817,100	1,817,100	1,817,100	1,817,100
Closing Balance	1,817,100	1,817,100	1,817,100	1,817,100

(B) Details of shares held by each shareholder holding more than 5% shares

Name of the shareholder	As at March 31, 2025		As at March 31, 2024	
	Number of shares held	% holding of equity shares	Number of shares held	% holding of equity shares
Cyient Limited (Holding company)	1,817,100	100.00%	1,817,100	100.00%

As per records of the Company, including its register of shareholders and other declarations received from shareholders regarding beneficial interest, the above shareholding represents both legal and beneficial ownership of shares.

(C) Details of Shares held by promoters at the end of the year

Name of the promoter	As at March 31, 2025		
	Number of shares held	% holding of equity shares	% Change during the Year
Cyient Limited (Holding company)	1,817,100	100.00%	0%

Name of the promoter	As at March 31, 2024		
	Number of shares held	% holding of equity shares	% Change during the Year
Cyient Limited (Holding company)	1,817,100	100.00%	0%

(D) Rights, preferences and restrictions attached to equity shares:

The Company has only one class of equity shares having a par value of ILS 1/- per share. Each holder of equity shares is entitled to one vote per share. In the event of liquidation, the equity shareholders are eligible to receive the remaining assets of the Company in proportion to their shareholding.

8. Other equity

Particulars	As at	
	March 31, 2025	March 31, 2024
Retained earnings		
Opening balance	307,049	317,049
Profit for the year	(10,000)	(10,000)
Closing balance	297,049	307,049

9. Trade Payables

Particulars	As at	
	March 31, 2025	March 31, 2024
Total outstanding dues*	505,651	495,651
Total	505,651	495,651

\*Trade payables are non-interest bearing and are normally settled on 0-30 days and includes amount payable to its related parties.

Ageing for trade payable	As at March 31, 2025						
	Unbilled	Not Due	Less than 1 year	1 - 2 years	2 - 3 years	More than 3 years	Total
Others	85,651	-	-	420,000	-	-	505,651
Disputed dues - Others	-	-	-	-	-	-	-
Balance at the end of the year	85,651	-	-	420,000	0	-	505,651

Ageing for trade payable	As at March 31, 2024						
	Unbilled	Not Due	Less than 1 year	1 - 2 years	2 - 3 years	More than 3 years	Total
Others	75,651	-	420,000	0	-	-	495,651
Disputed dues - Others	-	-	-	-	-	-	-
Balance at the end of the year	75,651	-	420,000	0	-	-	495,651

#### 10. Other liabilities

Particulars	As at	
	March 31, 2025	March 31, 2024
<b>Current</b>		
Advance from customers	28,515	28,515
Statutory Dues	15,058	15,058
<b>Total</b>	<b>43,573</b>	<b>43,573</b>

#### 11. Income Taxes

##### 11.1 Tax Expense

##### A. Income tax expense/(benefit) recognised in the statement of profit and loss

Particulars	As at	
	March 31, 2025	March 31, 2024
<b>Current Tax</b>		
In respect of current year	-	-
In respect of prior years	-	-
<b>Total</b>	<b>-</b>	<b>-</b>

##### B. Reconciliation of effective tax rate

The following is the reconciliation of the Company's effective tax rate for the year ended March 31, 2023 and 2024:

Particulars	As at	
	March 31, 2025	March 31, 2024
Profit before tax	(10,000)	(10,000)
Enacted Tax Rate	23%	23%
Computed expected tax expense	(2,300)	(2,300)
Effect of expenses that are deductible in determining taxable profit	2,300	2,300
Income tax expense	-	-
<b>Effective tax rate</b>	<b>0.0%</b>	<b>0.0%</b>

##### 11.2 Income tax assets and liabilities

Particulars	As at	
	March 31, 2025	March 31, 2024
<b>Current</b>		
Income tax assets, net		
Income tax asset	183,554	183,554
<b>Total</b>	<b>183,554</b>	<b>183,554</b>

#### 12. Revenue from operations

Particulars	For the year ended March 31, 2025	For the year ended March 31, 2023
Revenue from services	-	-
<b>Total</b>	<b>-</b>	<b>-</b>

##### 1. Disaggregated revenue information

The table below presents disaggregated revenues from contracts with customers by contract type and geography. The Company believes that this disaggregation best depicts how the nature, amount, timing and uncertainty of revenues and cash flows are affected.

Particulars	For the year ended	
	March 31, 2025	March 31, 2024
<b>Revenues by contract type</b>		
Services	-	-
<b>Total</b>	<b>-</b>	<b>-</b>
<b>Revenues by Geography</b>		
India	-	-
<b>Total</b>	<b>-</b>	<b>-</b>
<b>Revenues by Timing of recognition</b>		
Goods and services transferred		
- At a point in time	-	-
- Over time	-	-
<b>Total</b>	<b>-</b>	<b>-</b>

**Cyient Israel India Limited****Notes forming part of the financial statements**

(All amounts in ILS, unless otherwise stated)

**13. Other income**

Particulars	For the year ended March 31, 2025	For the year ended March 31, 2024
Miscellaneous income	-	-
<b>Total</b>	<b>-</b>	<b>-</b>

**14. Employee benefits expense**

Particulars	For the year ended March 31, 2025	For the year ended March 31, 2024
Salaries and wages, including bonus	-	-
<b>Total</b>	<b>-</b>	<b>-</b>

**15. Other expenses**

Particulars	For the year ended March 31, 2025	For the year ended March 31, 2024
Legal and professional charges	-	-
Provisions, no longer required	-	-
Rates and taxes	-	-
Foreign exchange loss (net)	-	-
Auditor's remuneration (excluding applicable taxes)	10,000	10,000
Miscellaneous expenses	-	-
<b>Total</b>	<b>10,000</b>	<b>10,000</b>